NCT02240888View on ClinicalTrials.gov

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2018

Conditions
RASLEVasculitisSclerodermaSjögrensSyndrome
Interventions
BIOLOGICAL

0,5 mg Prevenar i.m.

BIOLOGICAL

0,5 mg seasonal influenza vaccine i.m.

Trial Locations (1)

SE-22185

Skåne University hospital, Dept of rheumatology, Lund

All Listed Sponsors
lead

Region Skane

OTHER

NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response | Biotech Hunter | Biotech Hunter